Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 692-701

  Roglans, Núria ^a   Bellido, Antonia ^a   Rodríguez, Cristina ^a   Cabrero, Àgatha ^a   Novell, Ferran ^a   Ros, Emilio ^a   Zambón, Daniel ^a   Laguna, Juan C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; ACYL COENZYME A OXIDASE; APOLIPOPROTEIN A1; BEZAFIBRATE; BIOLOGICAL MARKER; CARNITINE PALMITOYLTRANSFERASE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHOLECYSTECTOMY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTIVE SURGERY; ENZYME ACTIVITY; FEMALE; GALLSTONE; HOSPITAL; HUMAN; HUMAN TISSUE; LIVER; MALE; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY; WILD TYPE;

ACYL-COA OXIDASE; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BEZAFIBRATE; CARNITINE O-PALMITOYLTRANSFERASE; CHOLECYSTECTOMY; CHOLELITHIASIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DNA PRIMERS; FEMALE; GEMFIBROZIL; HUMANS; LIVER; MALE; MIDDLE AGED; OXIDOREDUCTASES; POLYMERASE CHAIN REACTION; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STEAROYL-COA DESATURASE; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0036908881     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.128605     Document Type: Article

References (38)

1. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998;81:912-7.
2. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrate in human apolipoprotein A-I transgenic mice. J Clin Invest 1996;97:2408-16.
3. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-48.
4. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-12.
5. Smith SA. Peroxisomal proliferator activated receptors (PPARs): Molecular targets for hypolipidaemic agents and insulin sensitisers. Pharmacol Rev Commun 1996;8:57-64.
6. Desverge B, Wahli W. Peroxisomal proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999;20:649-88.
7. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 1997;272:27307-12.
8. Lock EA, Mitchell AM, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol 1980;29:145-63.
9. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPARs). Cell 1992;68:879-87.
10. Peters JM, Cattley RC, González FJ. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14, 643. Carcinogenesis 1997;18:2029-33.
11. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Reg Toxicol Pharmacol 1998;27:47-60.
12. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
13. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 1994;3-4:157-66.
14. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK. Identification of a peroxisome proliferator responsive element upstream of the human peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 1996;271:2147-55.
15. Palmer CNA, Hsu M-H, Griffin KJ, Raucy JL, Johson EF. Peroxisome proliferator activated receptor-α in human liver. Mol Pharmacol 1998;53:14-22.
16. Gervois P, Pineda I, Chinetti G, Grötzinger T, Dubois G, Fruchart JC, et al. A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol Endocrinol 1999;13:1535-49.
17. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-91.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-506.
19. Heuck CC, Erbe I, Flint-Hansen P. Immunonephelometric determination of apolipoprotein A-I in hyperlipoproteinemic serum. Clin Chem 1983;29:120-5.
20. Vander Heiden GL, Sasse EA, Yorde DE, Madiedo G, Barboriak JJ. Examination of a competitive enzyme-linked immunoassay (CELIA) technique and laser nephelometric immunoassay technique for measurement of apolipoprotein B. Clin Chim Acta 1983;135:209-18.
21. Rodríguez C, Noé V, Cabrero A, Ciudad CJ, Laguna JC. Differences in the formation of PPARα-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration. Mol Pharmacol 2000;58:185-93.
22. Mamdani MM, van Walraven C, Bica A, Williams JI, Naylor CD. Is there an association between lipid-lowering drugs and cholecystectomy? Am J Med 2000;108:418-21.
23. Einarsson K, Angelin B. Hyperlipoproteinemia, hypolipidemic treatment, and gallstone disease. Atheroscler Rev 1986;15:67-97.
24. Bertolotti M, Concari M, Loria P, Abate N, Pinetti A, Guicciardi ME, et al. Effects of different phenotypes of hypercholesterolemia and of treatment with fibric acid derivatives on the rates of cholesterol 7α-hydroxylation in humans. Arterioscler Thromb Vasc Biol 1995;15:1064-9.
25. Alegret M, Verd JC, Díaz C, Hernández G, Adzet T, Sánchez RM, et al. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur J Pharmacol 1998;347:283-91.
26. Marrapodi M, Chiang JYL. Peroxisome proliferator-activated receptor α(PPARα) and agonist inhibit cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J Lipid Res 2000;41:514-20.
27. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine LM, Branellec D, et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 1999;99:2445-51.
28. Louet JF, Le May C, Pégorier JP, Decaux JF, Girard J. Regulation of liver carnitine palmitoyltransferase I gene expression by hormones and fatty acids. Biochem Soc Trans 2001;29:310-6.
29. Vázquez M, Muñoz S, Alegret M, Adzet T, Merlos M, Laguna JC. Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. Br J Pharmacol 1995;116:2067-75.
30. Vessby B, Lithell H. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum. Atherosclerosis 1990;82:137-43.
31. Alegret M, Cerqueda E, Ferrando R, Vázquez M, Sánchez RM, Adzet T, et al. Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates. Relationship with their activity as peroxisome proliferators. Br J Pharmacol 1995;114:1351-8.
32. Rodriguez C, Cabrero A, Roglans N, Adzet T, Sánchez RM, Vázquez M, et al. Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells. Biochem Pharmacol 2001;61:357-64
33. Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). Progr Lipid Res 1995;34:139-50.
34. Baluuboer BJ, van Holsteijn CW, Bleumink R, Mennes WC, van Pelt FN, Yap SH, et al. The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochem Pharmacol 1990;40:521-528.
35. Perrone CE, Shao L, Williams GM. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 1998;150:277-286.
36. Gebel T, Arand M, Oesch F. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett 1992;309:37-40.
37. Inoue I, Noji S, Shen MS, Takahashi K, Katayama S. The peroxisome proliferator-activated receptor α (PPARα) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level. Biochem Biophys Res Commun 1997;237:606-10.
38. Hsu M-H, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor α in HepG2 cells. J Biol Chem 2001;276:27950-8.